Innoviva 관리

관리 기준 확인 4/4

Innoviva CEO는 Pavel Raifeld, May2020 에 임명되었습니다 의 임기는 4.5 년입니다. 총 연간 보상은 $ 868.65K, 55.8% 로 구성됩니다. 55.8% 급여 및 44.2% 보너스(회사 주식 및 옵션 포함). 는 € 214.59K 가치에 해당하는 회사 주식의 0.019% 직접 소유합니다. 214.59K. 경영진과 이사회의 평균 재임 기간은 각각 2.9 년과 6.8 년입니다.

주요 정보

Pavel Raifeld

최고 경영자

US$868.6k

총 보상

CEO 급여 비율	55.8%
CEO 임기	4.5yrs
CEO 소유권	0.02%
경영진 평균 재임 기간	2.9yrs
이사회 평균 재임 기간	6.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Pavel Raifeld 의 보수는 Innoviva 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	US$65m
Jun 30 2024	n/a	n/a	US$145m
Mar 31 2024	n/a	n/a	US$181m
Dec 31 2023	US$869k	US$485k	US$180m
Sep 30 2023	n/a	n/a	US$50m
Jun 30 2023	n/a	n/a	US$233m
Mar 31 2023	n/a	n/a	US$233m
Dec 31 2022	US$2m	US$440k	US$214m
Sep 30 2022	n/a	n/a	US$293m
Jun 30 2022	n/a	n/a	US$99m
Mar 31 2022	n/a	n/a	US$188m
Dec 31 2021	US$1m	US$391k	US$266m
Sep 30 2021	n/a	n/a	US$309m
Jun 30 2021	n/a	n/a	US$265m
Mar 31 2021	n/a	n/a	US$253m
Dec 31 2020	US$2m	US$222k	US$224m

보상 대 시장: Pavel 의 총 보상 ($USD 868.65K ) German 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 1.46M ).

보상과 수익: Pavel 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Pavel Raifeld (40 yo)

4.5yrs

테뉴어

US$868,648

보상

Mr. Pavel Raifeld, CFA, is Director of La Jolla Pharmaceutical Company since August 22, 2022. He serves as Chief Executive Officer of Innoviva, Inc. since May 2020. He is a seasoned healthcare executive wi...

리더십 팀

이름	위치	테뉴어	보상	소유권
Pavel Raifeld	Chief Executive Officer	4.5yrs	US$868.65k	0.019% € 214.6k
Stephen Basso	Chief Financial Officer	1.3yrs	US$1.18m	데이터 없음
Marianne Zhen	Chief Accounting Officer & Secretary	6.3yrs	US$924.21k	0.073% € 838.9k
Patricia Drake	Chief Commercial Officer-Innoviva Specialty Therapeutics	less than a year	데이터 없음	데이터 없음

2.9yrs

평균 재임 기간

56.5yo

평균 연령

경험이 풍부한 관리: HVE 의 관리팀은 경험 ( 2.9 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jules Haimovitz	Independent Director	6.8yrs	US$446.02k	0.19% € 2.1m
Sapna Srivastava	Independent Director	1.8yrs	US$547.11k	0.041% € 468.2k
Derek Small	Independent Director	less than a year	데이터 없음	데이터 없음
Odysseas Kostas	Independent Director	6.9yrs	US$331.18k	0.17% € 2.0m
Sarah Schlesinger	Independent Director	6.8yrs	US$367.25k	0.17% € 1.9m
Mark DiPaolo	Independent Director	6.8yrs	US$396.59k	0.17% € 1.9m

6.8yrs

평균 재임 기간

52.5yo

평균 연령

경험이 풍부한 이사회: HVE 의 이사회는 경험(평균 재직 기간 6.8 년)으로 간주됩니다.

Innoviva 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc. Appoints Patricia Drake as Chief Commercial Officer

Innoviva, Inc., Annual General Meeting, Jun 17, 2024

Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty Therapeutics

Chief Accounting Officer & Secretary recently sold €142k worth of stock

Innoviva, Inc. Appoints Stephen Basso as Chief Financial Officer

Innoviva, Inc. Announces Resignation of Deborah L. Birx as Member of the Board of Directors and Chair of the Audit Committee

Recent updates

Third quarter 2024 earnings released: EPS: US$0.019 (vs US$1.26 in 3Q 2023)

New minor risk - Financial position

New minor risk - Profit margin trend

Second quarter 2024 earnings released: US$0.56 loss per share (vs US$0.02 profit in 2Q 2023)

Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc. Appoints Patricia Drake as Chief Commercial Officer

New minor risk - Financial position

Now 21% undervalued after recent price drop

First quarter 2024 earnings released: EPS: US$0.58 (vs US$0.51 in 1Q 2023)

Innoviva, Inc., Annual General Meeting, Jun 17, 2024

Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.’s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Full year 2023 earnings released: EPS: US$2.75 (vs US$3.07 in FY 2022)

Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty Therapeutics

Chief Accounting Officer & Secretary recently sold €142k worth of stock

Third quarter 2023 earnings released: EPS: US$1.26 (vs US$3.81 in 3Q 2022)

Innoviva, Inc. Appoints Stephen Basso as Chief Financial Officer

Innoviva Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Nasdaq’s Audit Committee Composition Requirements

New major risk - Financial position

Second quarter 2023 earnings released: EPS: US$0.02 (vs US$0.013 in 2Q 2022)

Innoviva, Inc. Announces Resignation of Deborah L. Birx as Member of the Board of Directors and Chair of the Audit Committee

First quarter 2023 earnings released: EPS: US$0.51 (vs US$0.23 in 1Q 2022)

Full year 2022 earnings released: EPS: US$3.07 (vs US$3.24 in FY 2021)

Innoviva, Inc. Announces Appointment of Sapna Srivastava to the Board of Directors

Innoviva, Inc Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam

Third quarter 2022 earnings released: EPS: US$3.81 (vs US$1.04 in 3Q 2021)

Innoviva, Inc. (NasdaqGS:INVA) announces an Equity Buyback for $100 million worth of its shares.

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of La Jolla Pharmaceutical Company (NasdaqCM:LJPC).

Second quarter 2022 earnings released: EPS: US$0.013 (vs US$1.01 in 2Q 2021)

Royalty Pharma plc (NasdaqGS:RPRX) completed the acquisition of 15% stake in Theravance Respiratory Company, LLC from Innoviva, Inc. (NasdaqGS:INVA).

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX) from a group of shareholders.

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX) from a group of shareholders.

First quarter 2022 earnings released: EPS: US$0.23 (vs US$0.93 in 1Q 2021)

Investor sentiment improved over the past week

Innoviva, Inc. (NasdaqGS:INVA) submitted a non-binding proposal to acquire all of the remaining shares of Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX).

Independent Chairman of the Board recently bought €216k worth of stock

Innoviva, Inc. (NasdaqGS:INVA) announces an Equity Buyback for 32,000,000 shares, representing 32% for $392 million.

First quarter 2021 earnings released: EPS US$0.93 (vs US$0.65 in 1Q 2020)

Innoviva, Inc. Appoints Deborah L. Birx to its Board of Directors

Full year 2020 earnings released: EPS US$2.22 (vs US$1.56 in FY 2019)

Revenue beats expectations

Full year 2020 earnings released: EPS US$2.21 (vs US$1.56 in FY 2019)

Revenue beats expectations

New 90-day high: €10.20

New 90-day high: €10.00

Investor sentiment improved over the past week

Innoviva, Inc. Enters into Strategic Partnership with Sarissa Capital Management LP

Third quarter earnings released

New 90-day low: €8.40

New 90-day low: €9.25

New 90-day low - €10.60

New 90-day low - €11.10

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령